TORONTO--(BUSINESS WIRE)--Nov. 17, 2005--OccuLogix, Inc. (NASDAQ:RHEO)(TSX:RHE) today announced that all final study visits have been completed for the pivotal (phase III) MIRA-1 Trial. In December 2004, OccuLogix completed enrollment for participation in MIRA-1, or Multicenter Investigation of Rheopheresis for AMD, its pivotal stage clinical trial using its RHEO(TM) System to treat the dry form of age-related macular degeneration (“Dry AMD”). MIRA-1 is a multi-center, randomized (2:1), double-masked and placebo-controlled trial designed to evaluate the safety and efficacy of RHEO(TM) Therapy in patients with intermediate-to-late stage, or Category 3 and Category 4, Dry AMD. If successful, MIRA-1 is expected to support OccuLogix’s application to the U.S. Food and Drug Administration (“FDA”) for approval to market its RHEO(TM) System in the United States.
